Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

WCLC 2019：mNSCLC中的敏感性或耐药性突变

2019-09-09 Allan MedSci原创

mNSCLCWCLC耐药性突变敏感性突变
关注

在2019年WCLC上，来自纽约哥伦比亚大学医学中心的N. Rizvi博士介绍了III期MYSTIC研究的最新情况，该研究显示，STK11或KEAP1基因突变的转移性非小细胞肺癌患者使用免疫疗法的结果较差。在使用tremelimumab的durvalumab的患者中，与ARID1A野生型相比，ARID1A突变型患者的存活益处更好。

对于抗PD-L1联合抗CTLA-4疗法，基因改变和治疗反应之间的关系尚未得到很好的表征。在2019年WCLC上，来自纽约哥伦比亚大学医学中心的N. Rizvi博士介绍了III期MYSTIC研究的最新情况，该研究显示，STK11或KEAP1基因突变的转移性非小细胞肺癌患者使用免疫疗法的结果较差。在使用tremelimumab的durvalumab的患者中，与ARID1A野生型相比，ARID1A突变型患者的存活益处更好。

MYSTIC试验是一项随机、开放标签、多中心的全球III期试验，评估了durvalumab单药治疗或durvalumab联合tremelimumab治疗转移性非小细胞肺癌的有效性，该试验在17个国家的203个地点进行。


原始出处：

http://www.firstwordpharma.com/node/1664690?tsid=4#axzz5yvEPt24Y

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085980, encodeId=7c1b208598092, content=<a href='/topic/show?id=78f6803846c' target=_blank style='color:#2F92EE;'>#耐药性突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80384, encryptionId=78f6803846c, topicName=耐药性突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Wed Sep 11 18:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693964, encodeId=ab761693964e1, content=<a href='/topic/show?id=a1e61205edb' target=_blank style='color:#2F92EE;'>#mNSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12057, encryptionId=a1e61205edb, topicName=mNSCLC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 12:12:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388460, encodeId=be151388460b5, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412369, encodeId=df6814123693c, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039714, encodeId=39c11039e142b, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Sep 09 12:12:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-09-11 zzc2211

    #耐药性突变#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2085980, encodeId=7c1b208598092, content=<a href='/topic/show?id=78f6803846c' target=_blank style='color:#2F92EE;'>#耐药性突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80384, encryptionId=78f6803846c, topicName=耐药性突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Wed Sep 11 18:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693964, encodeId=ab761693964e1, content=<a href='/topic/show?id=a1e61205edb' target=_blank style='color:#2F92EE;'>#mNSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12057, encryptionId=a1e61205edb, topicName=mNSCLC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 12:12:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388460, encodeId=be151388460b5, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412369, encodeId=df6814123693c, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039714, encodeId=39c11039e142b, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Sep 09 12:12:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2020-05-12 智者为医08

    #mNSCLC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2085980, encodeId=7c1b208598092, content=<a href='/topic/show?id=78f6803846c' target=_blank style='color:#2F92EE;'>#耐药性突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80384, encryptionId=78f6803846c, topicName=耐药性突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Wed Sep 11 18:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693964, encodeId=ab761693964e1, content=<a href='/topic/show?id=a1e61205edb' target=_blank style='color:#2F92EE;'>#mNSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12057, encryptionId=a1e61205edb, topicName=mNSCLC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 12:12:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388460, encodeId=be151388460b5, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412369, encodeId=df6814123693c, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039714, encodeId=39c11039e142b, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Sep 09 12:12:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-09-11 ms5236388012055669

    #敏感性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2085980, encodeId=7c1b208598092, content=<a href='/topic/show?id=78f6803846c' target=_blank style='color:#2F92EE;'>#耐药性突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80384, encryptionId=78f6803846c, topicName=耐药性突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Wed Sep 11 18:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693964, encodeId=ab761693964e1, content=<a href='/topic/show?id=a1e61205edb' target=_blank style='color:#2F92EE;'>#mNSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12057, encryptionId=a1e61205edb, topicName=mNSCLC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 12:12:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388460, encodeId=be151388460b5, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412369, encodeId=df6814123693c, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039714, encodeId=39c11039e142b, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Sep 09 12:12:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-09-11 木头人514

    #WCLC#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2085980, encodeId=7c1b208598092, content=<a href='/topic/show?id=78f6803846c' target=_blank style='color:#2F92EE;'>#耐药性突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80384, encryptionId=78f6803846c, topicName=耐药性突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Wed Sep 11 18:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693964, encodeId=ab761693964e1, content=<a href='/topic/show?id=a1e61205edb' target=_blank style='color:#2F92EE;'>#mNSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12057, encryptionId=a1e61205edb, topicName=mNSCLC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 12:12:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388460, encodeId=be151388460b5, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412369, encodeId=df6814123693c, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Wed Sep 11 00:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039714, encodeId=39c11039e142b, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Sep 09 12:12:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-09-09 肿肿

    NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了

    0

Baidu
map
Baidu
map
Baidu
map